The status of pharmacotherapy for autism spectrum disorders
The DOI matches its Crossref record; 35 of the 35 references it cites were found in a registry or an index.
Abstract
The use of pharmacologic agents as a component of treatment for children and adults with autism spectrum disorders is common and a substantial body of literature describing controlled and open-label clinical trials now exists to guide clinical practice. Empiric evidence of efficacy of risperidone, methylphenidate and some selective serotonin re-uptake inhibitors for maladaptive behaviors commonly associated with autism spectrum disorders has increased substantially in recent years. Preliminary controlled trials of valproate, atomoxetine, alpha-2 adrenergic agonists and olanzapine are promising. In addition to traditional psychotropic medications, investigators have examined the potential role of a variety of agents with glutamatergic or cholinergic mechanisms, and the results warrant further investigation. Although psychotropic medications are effective in treating some important associated behaviors, evidence of significant impact on the core features of autism spectrum disorders is very limited.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Comorbid psychiatric disorders in children with autism: interview development and rates of disorders
Leyfer, O. T., Folstein, S. E., Bacalman, S., Davis, N. O., Dinh, E., Morgan, J., Tager-Flusberg, H., & Lainhart, J. E. (2006) · Journal of Autism and Developmental Disorders · doi:10.1007/s10803-006-0123-0 · Cited by 1,637 · cited 1×
“Standardized behavior checklists and structured interviews may be helpful in making additional psychiatric diagnoses [247,248] .”
BackgroundRisperidone in Children with Autism and Serious Behavioral Problems
McCracken, J. T., McGough, J., Shah, B., Cronin, P., Hong, D., Aman, M. G., Arnold, L. E., Lindsay, R., Nash, P., Hollway, J., et al. (2002) · New England Journal of Medicine · doi:10.1056/nejmoa013171 · Cited by 1,574 · cited 6×
“Aggression, explosive outbursts, self-injury, irritability Atypical antipsychotic (risperidone*, aripiprazole, olanzapine, quetiapine, ziprasidone) [50-57,60,70-79,83,84,86-88]”
BackgroundInfluentialThe impact of behaviour problems on caregiver stress in young people with autism spectrum disorders
Lecavalier, L., Leone, S., & Wiltz, J. (2006) · Journal of Intellectual Disability Research · doi:10.1111/j.1365-2788.2005.00732.x · Cited by 1,163 · cited 1×
“Behavior problems are common in individuals with ASDs and are strongly associated with caregiver stress [5-10] .”
BackgroundOxytocin Increases Retention of Social Cognition in Autism
Hollander, E., Bartz, J., Chaplin, W., Phillips, A., Sumner, J., Soorya, L., Anagnostou, E., & Wasserman, S. (2007) · Biological Psychiatry · doi:10.1016/j.biopsych.2006.05.030 · Cited by 693 · cited 1×
“found that parenteral administration of synthetic oxytocin was significantly more effective than placebo in reducing repetitive behavior and facilitating processing and retention of social information (ability to accurately assign emotional significance to speech intonation) in 15 adults with ASDs [224,225] .”
BackgroundOxytocin Infusion Reduces Repetitive Behaviors in Adults with Autistic and Asperger's Disorders
Hollander, E., Novotny, S., Hanratty, M., Yaffe, R., DeCaria, C. M., Aronowitz, B. R., & Mosovich, S. (2003) · Neuropsychopharmacology · doi:10.1038/sj.npp.1300021 · Cited by 689 · cited 1×
“found that parenteral administration of synthetic oxytocin was significantly more effective than placebo in reducing repetitive behavior and facilitating processing and retention of social information (ability to accurately assign emotional significance to speech intonation) in 15 adults with ASDs [224,225] .”
BackgroundInternet survey of treatments used by parents of children with autism.
Green, V. A., Pituch, K. A., Itchon, J., Choi, A., O’Reilly, M., & Sigafoos, J. (2006) · Research in Developmental Disabilities · doi:10.1016/j.ridd.2004.12.002 · Cited by 617 · cited 1×
“1 Psychopharmacology Recent caregiver surveys indicate that 46 – 52% of individuals with ASDs are treated with psychotropic medication [14-17] .”
BackgroundLecavalier, L. (2006) · Journal of Autism and Developmental Disorders · doi:10.1007/s10803-006-0147-5 · Cited by 569
(2005) · Archives of General Psychiatry · doi:10.1001/archpsyc.62.11.1266 · Cited by 521
Aman, M. G., De Smedt, G., Derivan, A., Lyons, B., Findling, R. L., & Risperidone Disruptive Behavior Study Group (2002) · American Journal of Psychiatry · doi:10.1176/appi.ajp.159.8.1337 · Cited by 475
Fombonne, E., Zakarian, R., Bennett, A., Meng, L., & McLean-Heywood, D. (2006) · Pediatrics · doi:10.1542/peds.2005-2993 · Cited by 399 · cited 1×
“6 per 1000, and the ratio of males to females is ∼ 4:1 [3,4] .”
Background
Cited by
Management of Children With Autism Spectrum Disorders
Myers, S. M., Johnson, C. P., & the Council on Children With Disabilities (2007) · Pediatrics · doi:10.1542/peds.2007-2362 · Cited by 1,125
Self-citationOxidative stress-related biomarkers in autism: Systematic review and meta-analyses
Frustaci, A., Neri, M., Cesario, A., Adams, J. B., Domenici, E., Dalla Bernardina, B., & Bonassi, S. (2012) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2012.03.011 · Cited by 365
Co-occurrence of ADHD and autism spectrum disorders: phenomenology and treatment
Reiersen, A. M., & Todd, R. D. (2008) · Expert Review of Neurotherapeutics · doi:10.1586/14737175.8.4.657 · Cited by 189
“9 Greene RW, Biederman J, Faraone SV, Ouellette CA, Penn C, Griffin SM. Toward a new psychometric definition of social disability in children with attention-deficit hyperactivity disorder. J. Am. Acad. Child Adolesc. Psychiatry 35(5), 571–578 (1996).”
BackgroundBacher, I., Wu, B., Shytle, D. R., & George, T. P. (2009) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656560903329102 · Cited by 96
A review of recent reports on autism: 1000 studies published in 2007
Hughes, J. R. (2008) · Epilepsy & Behavior · doi:10.1016/j.yebeh.2008.06.015 · Cited by 76
Metadata
- Authors
- Myers, S. M.
- Venue
- Expert Opinion on Pharmacotherapy
- Publisher
- Informa Healthcare
- Published
- 2007-08
- Volume
- 8
- Issue
- 11
- Pages
- 1579-1603
- ISSN
- 1465-6566 (ISSN-L)
- 1744-7666
- OpenAlex
- W2005281014
- Cited by
- 69
- References
- 35
- FWCI
- 3.25
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: The status of pharmacotherapy for autism spectrum disorders. https://app.cochat.ai/papers/10.1517/14656566.8.11.1579
- The paper
- Myers, S. M. (2007). The status of pharmacotherapy for autism spectrum disorders. Expert Opinion on Pharmacotherapy. https://doi.org/10.1517/14656566.8.11.1579
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.